Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

O-GlcNAc transferase suppresses necroptosis and liver fibrosis.

Zhang B, Li MD, Yin R, Liu Y, Yang Y, Mitchell-Richards KA, Nam JH, Li R, Wang L, Iwakiri Y, Chung D, Robert ME, Ehrlich BE, Bennett AM, Yu J, Nathanson MH, Yang X.

JCI Insight. 2019 Nov 1;4(21). pii: 127709. doi: 10.1172/jci.insight.127709.

2.

Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma.

Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Mitchell Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Lo Re V  III.

Cancer Epidemiol Biomarkers Prev. 2019 Oct 1. doi: 10.1158/1055-9965.EPI-19-0503. [Epub ahead of print]

PMID:
31575557
3.

Network Analysis of Autopsy Diagnoses: Insights into the "Cause of Death" from Unbiased Disease Clustering.

Celli R, Divo M, Colunga M, Celli B, Mitchell-Richards KA.

J Pathol Inform. 2018 Oct 9;9:35. doi: 10.4103/jpi.jpi_20_18. eCollection 2018.

4.

Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH.

Wang J, Cho NL, Zauber AG, Hsu M, Dawson D, Srivastava A, Mitchell-Richards KA, Markowitz SD, Bertagnolli MM.

Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):728-736. doi: 10.1158/1055-9965.EPI-17-0573. Epub 2018 May 16.

5.

Nonalcoholic fatty liver disease impairs expression of the type II inositol 1,4,5-trisphosphate receptor.

Khamphaya T, Chukijrungroat N, Saengsirisuwan V, Mitchell-Richards KA, Robert ME, Mennone A, Ananthanarayanan M, Nathanson MH, Weerachayaphorn J.

Hepatology. 2018 Feb;67(2):560-574. doi: 10.1002/hep.29588. Epub 2018 Jan 2.

6.

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).

Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE; Alliance for Clinical Trials in Oncology.

J Clin Oncol. 2017 Jul 1;35(19):2184-2192. doi: 10.1200/JCO.2016.71.3743. Epub 2017 May 10.

7.

Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination.

Vilarinho S, Erson-Omay EZ, Mitchell-Richards K, Cha C, Nelson-Williams C, Harmancı AS, Yasuno K, Günel M, Taddei TH.

J Hepatol. 2017 Jul;67(1):186-191. doi: 10.1016/j.jhep.2017.03.009. Epub 2017 Mar 18.

8.

Nuclear Factor, Erythroid 2-Like 2 Regulates Expression of Type 3 Inositol 1,4,5-Trisphosphate Receptor and Calcium Signaling in Cholangiocytes.

Weerachayaphorn J, Amaya MJ, Spirli C, Chansela P, Mitchell-Richards KA, Ananthanarayanan M, Nathanson MH.

Gastroenterology. 2015 Jul;149(1):211-222.e10. doi: 10.1053/j.gastro.2015.03.014. Epub 2015 Mar 18.

9.

Post-translational regulation of the type III inositol 1,4,5-trisphosphate receptor by miRNA-506.

Ananthanarayanan M, Banales JM, Guerra MT, Spirli C, Munoz-Garrido P, Mitchell-Richards K, Tafur D, Saez E, Nathanson MH.

J Biol Chem. 2015 Jan 2;290(1):184-96. doi: 10.1074/jbc.M114.587030. Epub 2014 Nov 5.

10.

Disseminated enteroinvasive aspergillosis in a critically ill patient without severe immunocompromise.

Fieber JH, Atladóttir J, Solomon DG, Maerz LL, Reddy V, Mitchell-Richards K, Longo WE.

J Surg Case Rep. 2013 Nov 4;2013(11). pii: rjt091. doi: 10.1093/jscr/rjt091.

Supplemental Content

Loading ...
Support Center